TWI291463B - Thiazolidinedione hydrochloride hydrate, pharmaceutical composition comprising the same and process for preparing the same - Google Patents
Thiazolidinedione hydrochloride hydrate, pharmaceutical composition comprising the same and process for preparing the same Download PDFInfo
- Publication number
- TWI291463B TWI291463B TW089107634A TW89107634A TWI291463B TW I291463 B TWI291463 B TW I291463B TW 089107634 A TW089107634 A TW 089107634A TW 89107634 A TW89107634 A TW 89107634A TW I291463 B TWI291463 B TW I291463B
- Authority
- TW
- Taiwan
- Prior art keywords
- hydrate
- compound
- diabetes
- same
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 7
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- KPSTVAVPUBYGNX-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione hydrate hydrochloride Chemical compound O.Cl.S1C(NC(C1)=O)=O KPSTVAVPUBYGNX-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 23
- 206010012601 diabetes mellitus Diseases 0.000 claims description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 9
- 230000008025 crystallization Effects 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 8
- -1 hydrochloric acid ions Chemical class 0.000 claims description 7
- 239000000376 reactant Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 abstract description 14
- 238000000634 powder X-ray diffraction Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 abstract 1
- 238000002329 infrared spectrum Methods 0.000 abstract 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 238000000034 method Methods 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002079 cooperative effect Effects 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- VBYZSBGMSZOOAP-UHFFFAOYSA-N molecular hydrogen hydrate Chemical compound O.[H][H] VBYZSBGMSZOOAP-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229940125708 antidiabetic agent Drugs 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- XTEGARKTQYYJKE-UHFFFAOYSA-N chloric acid Chemical compound OCl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-N 0.000 description 2
- 229940005991 chloric acid Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000235503 Glomus Species 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122199 Insulin secretagogue Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 208000034699 Vitreous floaters Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000012042 active reagent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- LBZBTBQKZLLYDP-UHFFFAOYSA-N chloric acid hydrate Chemical compound O.OCl(=O)=O LBZBTBQKZLLYDP-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JYVHOGDBFNJNMR-UHFFFAOYSA-N hexane;hydrate Chemical compound O.CCCCCC JYVHOGDBFNJNMR-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- NMJORVOYSJLJGU-UHFFFAOYSA-N methane clathrate Chemical compound C.C.C.C.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O NMJORVOYSJLJGU-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- COWNFYYYZFRNOY-UHFFFAOYSA-N oxazolidinedione Chemical compound O=C1COC(=O)N1 COWNFYYYZFRNOY-UHFFFAOYSA-N 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
1291463 A7 B7 五、發明說明(3 ) 後回收所要的化合物。 適當的,該反應係在周遭溫度下進行但可使用任何方 便的溫度而產生所要的產物。 所要之化合物的回收通常包括使用例如二乙醚之適當 溶劑的結晶法。 於另一製備氫氯酸鹽水合物之方法中,將化合物⑴於 一適當含水有機溶劑,宜為丙_2_醇,之懸浮液用氫氯酸, 宜為濃氫氯酸,於任何溫度下處理,得到所要的產物,例 如’由20°C至30°C之溫度範圍,宜為周遭溫度。宜將該 反應混合物搖動或攪拌。上述最後的反應中水份的總量宜 為由約2%重量/體積至約20%重量/體積,例如10%重 量/體積。 上述製法可植入氫氯酸鹽水合物,但這並非必要。 於另一製備氫氯酸鹽水合物之方法中將一含有化合物 (I)於一適當有機溶劑中之溶液用氫氯酸處理而產生實質上 溶解的反應物,然後誘發出結晶反應而生成氫氣酸鹽水合 物。 上述最後的反應中水份的總量宜為由約2%重量/體 積至約20%重量/體積,例如10%重量/體積。 適當的有機溶劑為丙-2-醇等。適當的有機溶劑為乙腈 等。 於上述製法之一方面,例如,當有機溶劑為丙-2-醇等 時,實質上溶解之反應物宜藉著將反應於昇高溫度,例 如,由60°C至80°C之溫度範圍間,宜在65°C至75°C,例 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁) ώ9----l·—tr-------- 經濟部智慧財產局員工消費合作社印製 1291463 時 用 時 晶 A7 發明說明(4) 如’ 70°C時進行而得到。 法之n例如’t有機溶劑為乙赌等 声,=上溶解之反應物宜藉著將反應於周遭或昇高溫 又,且在周遭溫度時進行而得到。 =士述製法之-方面’例如,當有機溶劑為丙·2醇等 „反應冷却,财至周遭溫度,而紐結晶作 且在氣氣酸鹽水合物之種晶存在之下進行。 ^士述製法之另-方面’例如’ #有機溶劑為乙腈等 且猎者添加適當的辅溶劑,例如,二乙喊, =,宜在誠溫度且宜在氫驗财合物之種晶^ 之下進行。 、如果反應中水份含量適合於氫氯酸鹽水合物之形成, 上述製法中氫氣酸可以被任何適當的氫氯化物離子來源取 代。通常水份之適當含量至少為一莫耳當量且通常超過 之,例如,為上述製法中使用之等量。 ^除非另有特別說明,氫氣酸鹽水合物之結晶作用通常 係在低溫至周遭溫度,例如由Q纟机之範圍間,例如 25C時進行;或者結晶作用可在一昇高溫度,例如由耽 至,60C之範圍間,例如耽時開始,且然後藉著將溶劑 之酿度冷卻至周遭溫度或低溫,例如由〇至扣它,例如 25 C而完成。該結晶作用可藉植入氫氯酸鹽水合物結晶而 開始,但除非另有特別說明,此舉並非必要。 化合物⑴係根據已知過程製備,例如那些揭示於Ep 〇,306,228 及 W0 94/〇5659 巾者。EP 0,306,228 及 W〇 _6· 本紙張尺絲时關規格(210χ297 · (請先閱讀背面之注意事項再填寫本頁)
一·!· MB MB I I ϋ ϋ I ϋ ϋ I 經濟部智慧財產局員工消費合作社印製 1291463 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(5 ) 94/05659中所揭示之内容係合併至}文中作為參考。 “tir’預防伴隨著糖尿病之狀況,,-詞包括治療例如 =素㈣纽孩’高騰島麵症及錄糖 尿病。 糖尿病宜指π型糖尿病。 伴隨著糖尿病之狀況包括高血糖症及胰島素抵抗性及 肥胖症。其他伴隨著糖尿病之狀況包括高血I,心血管疾 病,尤其是動脈粥樣硬化症,某些進食障礙 、 f'伴隨著,,之障礙’例如’神經性厭食症,it 者攝食過里之IV礙,例如,肥胖症及善肌癖厭食症之病串、 對於食紅攝取食物之調節作用。其他伴隨著糖尿病之= 況包括多囊㈣巢_群及義醇料讀島素抵抗性。 本文中,伴隨著糖尿病之狀況的併發症包括腎疾 尤其是伴隨著u型糖尿紐展之m包括糖尿病的& 病,血管球性腎炎,血管球性硬化,腎病徵候群 = 性腎硬化及腎疾病末期。 ^ 如前所述,本發明之化合物具備有用的治療特性 發明因此提供氫氣酸鹽水化合物而用作為活性治療性物 質。 更特別的,本發明係提供氫氣酸鹽水合物以用來 及/或預防糖尿病,伴隨著糖尿病之狀況及其某些= 症。 ^ 該氫氯酸鹽水合物可單獨給藥或宜以亦包含製藥上。 接受之載_醫藥組成物給藥。錢鹽水合物^製= 木紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) ϋ 1 1 ·1 1 n 1^*OJ_ MB* MM MB MBS I MB* _ ^ (請先閱讀背面之注意事項再填寫本頁) 1291463 A7 B7 五、發明說明( \J/ 6 經濟部智慧財產局員工消費合作社印製 通常係如同前述公開案中為化合物⑴揭示者。 因此,本發明亦提供一包含氫氯酸鹽水合物及製藥上 為此之可接受載體的醫藥組成物。 該氫氯酸鹽水合物通常係以單位劑量型式給藥。 該活性化合物可依任何適當的途徑給藥但經常藉口服 或非經腸胃途徑給藥。為了此等用途,該化合物一般係以 合併有製藥載體,稀釋劑及/或賦形劑之醫藥組成物型式 使用,雖然組成物之正確型式自然係依據給藥之模式而 定。 組成物係藉著掺和而製備且係適用於口服,非經腸胃 、巧藥或局。卩給藥,且因此可以為錠劑,膠囊,口服液體製 劑,粉末,顆粒,錠片,糖錠,可重組式粉末,可注射及 可灌注之溶液或懸浮液、栓劑及經皮裝置之型式。由於其 車乂便於一般使用,以口服給藥組成物較適宜,特別是成型 的口服組成物。 口服給藥用之錠劑及膠囊通常係以單位劑量呈現,且 含有習用賦形劑,例如,黏合劑,充填劑,稀釋劑,成錠 劑’潤滑劑,崩散劑,染劑,香 货禾剎及潤濕劑。該錠劑 可根據技藝熟知之方法包埋。 所使狀適當域社_較,甘露㈣,乳糖 =他類似·。適當關散劑包括灣,聚 =及凝粉衍生物,例如殿粉乙醇酸鈉。適當的潤滑劑包 月桂醯硫_。 料樂上可接㈣潤濕劑包括 (CNS)A4 ^ (210 χ 29fi: 釐) (請先閱讀背面之注意事項再填寫本頁)
1291463 五、發明說明(7 ) 經濟部智慧財產局員工消費合作社印製 A7 B7 固態口服組成物可藉習用夕人 製備。可使用重覆的充填、成錠等方法 .t A 吧13呆而將活性試劑在使用大量充 ==成 的分布。當然,此等操作係習知 於已知技藝者。 口服液態製劑可以為,例如 ^ . 〗如’水性或油性懸浮液,溶 液,乳化液,糖漿,或酏劑,或 _ ^ 义可以於使用前與水或其他 適當載體重組之乾性產物呈現。 a 此等液態製劑可含有習用 ^劑’例㈣浮劑,例如,山梨糖醇,糖漿,甲基纖維 :、:明,’羥基乙基纖維素,羧基甲基纖維素 ,硬脂酸鋁 滅膠或氫化之可食性脂肪,乳化劑,例如,_脂,山梨 糖醇野單油_旨,或金合卿;非水性傾(其可包含可 艮1±油類)’例如,杏仁油,分餾之挪子油,油性醋類, 例如甘/由,伸丙基乙二醇,或乙基醇之g旨類;防腐劑, 例如,甲基或丙基對羥基苯甲酸酯或山梨酸,且如果想 要,可含有習用香味劑或染劑。 於非經腸胃給藥時,流體單位劑量型式係製成含有本 發明之化合物及一無菌載體。根據載體及濃度,該化合物 可為懸浮或溶解。非經腸胃給藥之溶液一般係藉著將活性 化合物溶解於載體及充填劑中,於填充至適當小瓶或安瓿 前殺菌並密封而製備。有利的是,輔助劑,例如,局部麻 醉劑’防腐劑及緩衝劑亦溶解於載體中。為了增進穩定 性’可將組成物於充填至小瓶後凍乾並於真空中移除水 份。 非經腸胃給藥之懸浮液實質上係依相同方式製備,除 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注咅?事項再填寫本頁)
五、發明說明(8 ) 經濟部智慧財產局員工消費合作社印製 1291463 了活性化合物係懸浮於載體中而代替了溶解且藉著在懸浮 於無菌載體之前暴露於環氧乙烷而殺菌。有利的是,組成 物中含有表面活性劑或潤濕劑以促進活性化合物之均勻分 佈。 此外,該氫氣酸鹽水合物可與其他抗糖尿病試劑,例 如’胰島素促泌素’例如,確醯脲,雙脈,例如,米甲 酉文精(metformin),α糖苷酶抑制劑,例如,爾卡波斯 (acarbose),召激動劑,及例如那些揭示於w〇 98/57649, W0 98/57634 ’ W0 98/57635 或 WO 98/57636 中之胰島素 合併使用。其他抗糖尿病試劑,其劑量及給藥之方法如同 於前公開案中提及者。於該組成中之氫氯酸鹽水合物的製 劑及其劑量一般係如同上述公開案中為化合物⑴所揭示 者。 如同慣例,該組成物通常會對所關係之醫藥治療寫出 或印出用法指導。 於本文中,,製藥上可接受”一詞包括人類及獸醫用之化 合物,組成物及組成份:例如,”製藥上可接受之鹽"一詞 包括獸醫可接受之鹽。 本發明又提供一種用來治療及/或預防人類或非人類 哺乳類之糖尿病,伴隨著糖尿病之狀況及其某些併發症之 方法,其包括將有效量,無毒性之氫氯酸鹽水合物給藥至 需要之人類或非人類哺乳類。 方便的,該活性組成份可如同本文於前所定義之醫藥 組成物般給藥,且此構成本發明之一特別的目的。 -10- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) (請先閱讀背面之注意事項再填寫本頁)
1291463
發明說明(9 經濟部智慧財產局員工消費合作社印製 本發明之另—目的提供氯氯酸鹽水合物 來治療及/或預防糖尿病,伴隨著糖尿病之壯備-種用 併發症之醫藥品的用途。 / 兄及其某些 於治療及/或預防糖尿病,伴隨著糖尿病 某些併發症時,該聽酸鹽水合物可以例 况= 述公開案中之劑量投服。 二揭不於前 本發明於上述治療中未顯示出不利的毒性效應。 下列實例係闡明本發明而非以任何方式限制之。 pLl : 5·[4-[2_(Ν_甲基-N_(2_吼咬基)胺基)乙氧基]辛基] 嗟唾烧_2,4_二_,氫氯—水合物(氫氯酸鹽水合物)之 ,備:於-含有5-[4_[2供甲基_Ν·(2_吼咬基)胺基)乙氧基] 卞基]噻唑烷-2,4-二酮(1〇克)於醋酸(1〇〇克)之溶液中加入 濃氫氣酸(10毫升)於15分鐘後,將澄清溶液用二乙醚(15〇 耄升)處理。將上層清液體傾析出來,並將殘質與新鮮二 乙醚(100毫升)一起攪拌。將液體再次傾析出來,並將該 稠油與新鮮二乙醚(50毫升)一起攪拌。將產物過濾出來並 用二乙醚清洗且於50°C真空中乾燥,得到標的化合物 (7.67克,66.5%),熔點為i〇〇_3°C,於150-4Ό再凝固及 再熔解。 例2 :將濃氫氣酸(1.0毫升)於21°C時加至一含有5-[‘ [2-(N-甲基-N-(2-吡啶基)胺基)乙氧基]苄基]唼唑炫_2,4-二 酮(4·〇克)於含丙_2-醇(100毫升)及水(10毫升)之混合物中 -11- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) _ —^9--------ltr---------· (請先閱讀背面之注意事項再填寫本頁) 291463
五、發明說明(10) 經濟部智慧財產局員工消費合作社印製 之經擾摔的懸浮液中。將混合物加溫至25〇c並於此溫度攪 摔1小時期間。藉過渡法收集產物,用丙-2_醇(20毫升)清 洗並於真空中乾燥,得到氫氣酸鹽水合物(3·8克)。 尤1^·將一含有ΗΗ2_(Ν·曱基·Ν_(2·。比啶基)胺基)乙氧 基]下基]噻唑烷-2,4·二酮(4·〇克),丙_2_醇(1〇〇毫升)及水 (ίο毫升)之混合物加溫至75t:並攪拌。將含水氫氯酸 (2·3Μ ’ 5.G㈣)加到此經櫈拌的懸浮液中並將產生的溶 液於1小時期間冷却至抓。將混合物植人氫氣酸鹽水合 物之結晶並攪拌3G分鐘。藉過澹法收集產物,得到白色 結晶固體之氫氣酸鹽水合物(3·9克)。 將濃氳氯酸(2·〇毫升)加至一含有5_[4_[2供甲基_ Ν-(2-吡啶基)胺基)乙氧基]苄基]噻唑烷_2,4_二酮(2〇克& 乙腈(20耄升)之混合物中並將混合物於21乞時攪拌直到產 ^-澄清溶液。將二乙醚(15毫升)加至_拌的溶液中接 著植入氫氯酸鹽水合物之結晶(2〇毫克)。於麟5分鐘 後,加入二乙醚(15毫升)並繼續攪拌丨小時。藉過濾法收 集產物,用二乙醚/乙腈(2 :卜2G毫升)清洗並於真空中 乾燥5小時,得到白色結晶固體之氫氯酸鹽水合物(u 克)。 * 將一含有HH2.甲基_N〇比咬基)胺基)乙氧 基]苄基]噻唑烷-2,4-二酮(1〇.〇克)及丙_2_醇〇4〇毫升)之混 -12- (請先閱讀背面之注意事項再填寫本頁)
I29l463 A7
五、發明說明(11) (請先閱讀背面之注音?事項再填寫本頁) 合物攪拌並加溫至60°C。將含水氳氯酸(4M,14毫升)加 到經擾拌的混合物巾並將溫度上升至聰且維持於此溫度 10为鐘。將產生的澄清溶液於大約丨小時期間冷却至21 C。藉過濾法收集產物,用丙-2-醇(30毫升)清洗並於真空 中在五氧化二磷上乾燥20小時,得到白色結晶固體之氫 氯酸鹽水合物(1〇·4克)。 特徵資料:下列特徵資料係為氫氣酸鹽水合物生成者: Α.水份含量 其係以4·5%重量/重量用卡爾費雪(Karl Fischer)裝置 測定(一水合物之理論值為4.37%重量/重量)。 B.離子性氣 其係以8.7%重量/重量測定(一水合物之理論值為 8.61%重量/重量)。 C.紅外線 經濟部智慧財產局員工消費合作社印製 氫氣酸鹽水合物之礦物油分散作用的紅外線吸收光譜 係用尼古拉710 FT-IR分光計於2cm·1解析率得到。數據 於lcm·1區間記錄。所獲得之光譜示於圖〗。波峯位置如 下:3358, 3124, 2764, 1762, 1747, 1707, 1644, 1614, 1587, 1544, 1511, 1414, 1333, 1302, 1268, 1245, 1181, 1154, 1142, 1108, 1075, 1054, 1033, 1012, 988, 938, 905, 859, 833, 817, 760, 738, 716, 663, 652, 636, 620, 605, 564, 540, 525 及 13- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 291463 A7 B7 五、發明說明(i2) 505 cm' D.X-射線粉末繞射(XRPD) 下圖II所示為氫氯酸鹽水合物之XRPD圖型且表I 所示為氫氣酸鹽水合物之XRPD角及經計算之晶格間隔特 性之摘要。 用菲利浦PW 1710 X-射線粉末繞射儀(Cu X-射線源) 依下列給定之條件來產生粉末圖型: 陽極管: 發生器強度 發生器電流 起始角 終點角 步大小 每步時間:
Cu 40kV 30mA 3.5° 2Θ 35.0° 2Θ 0.020° 2Θ 2·3秒 (請先閱讀背面之注音?事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 -14- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Claims (1)
1291463 益 C8 _D8_ 六、申請專利範圍 中用一氫氯酸鹽離子源處理;或 (b)將一含有化合物(I)於含水有機溶劑中之懸浮液於 由2(TC至30°C之溫度範圍間用氫氯酸鹽離子源 處理;或 5 (c)將一含有化合物(I)於有機溶劑之溶液用氫氯酸鹽 離子源處理而得到實質上溶解之反應物,然後誘 發結晶作用而產生氫氣酸鹽水合物;且之後回收 所要的化合物。 6. —種用於治療糖尿病、伴隨著糖尿病之狀況及其某 10 些併發症之醫藥組成物,其係包含一有效,無毒性 量之如申請專利範圍第1項的水合物及為其之製藥 上可接受的載體。 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9909075.5A GB9909075D0 (en) | 1999-04-20 | 1999-04-20 | Novel pharmaceutical |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI291463B true TWI291463B (en) | 2007-12-21 |
Family
ID=10851922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW089107634A TWI291463B (en) | 1999-04-20 | 2000-04-24 | Thiazolidinedione hydrochloride hydrate, pharmaceutical composition comprising the same and process for preparing the same |
Country Status (42)
| Country | Link |
|---|---|
| EP (2) | EP1411054A1 (zh) |
| JP (2) | JP4283450B2 (zh) |
| KR (1) | KR100677815B1 (zh) |
| CN (2) | CN1327446A (zh) |
| AP (1) | AP1680A (zh) |
| AR (2) | AR023563A1 (zh) |
| AT (1) | ATE262524T1 (zh) |
| AU (1) | AU773112B2 (zh) |
| BG (1) | BG65428B1 (zh) |
| BR (1) | BR0009898A (zh) |
| CA (1) | CA2370270A1 (zh) |
| CO (1) | CO5170420A1 (zh) |
| CZ (1) | CZ300934B6 (zh) |
| DE (1) | DE60009276T2 (zh) |
| DK (1) | DK1173437T3 (zh) |
| DZ (1) | DZ3163A1 (zh) |
| EA (1) | EA004769B1 (zh) |
| EG (1) | EG23946A (zh) |
| ES (1) | ES2214267T3 (zh) |
| GB (1) | GB9909075D0 (zh) |
| HK (1) | HK1045304B (zh) |
| HR (1) | HRP20010771B1 (zh) |
| HU (1) | HUP0200785A3 (zh) |
| IL (1) | IL146077A0 (zh) |
| MA (1) | MA26784A1 (zh) |
| MX (1) | MXPA01010695A (zh) |
| MY (1) | MY125209A (zh) |
| NO (1) | NO320573B1 (zh) |
| NZ (1) | NZ515164A (zh) |
| OA (1) | OA11867A (zh) |
| PE (1) | PE20010047A1 (zh) |
| PL (1) | PL351115A1 (zh) |
| PT (1) | PT1173437E (zh) |
| RS (1) | RS50137B (zh) |
| SI (1) | SI1173437T1 (zh) |
| SK (1) | SK284990B6 (zh) |
| TR (1) | TR200103041T2 (zh) |
| TW (1) | TWI291463B (zh) |
| UA (1) | UA72245C2 (zh) |
| UY (1) | UY26113A1 (zh) |
| WO (1) | WO2000063206A2 (zh) |
| ZA (1) | ZA200108721B (zh) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9909075D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
| GB0014005D0 (en) * | 2000-06-08 | 2000-08-02 | Smithkline Beecham Plc | Novel pharmaceutical |
| SI1448559T1 (sl) * | 2001-11-21 | 2007-06-30 | Smithkline Beecham Plc | 5-(4-(2-(n-metil-n-(2-piridil)amino)etoksi)benzil-tiazolidin-2,4-dion- benzensulfonat; postopek za njegovo pripravo; njegovi polimorfi i, ii, iii; in njegova uporaba kot farmacevtska uäśinkovina |
| KR100450700B1 (ko) * | 2002-03-22 | 2004-10-01 | 주식회사종근당 | 티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물 |
| US20050105328A1 (en) * | 2003-11-17 | 2005-05-19 | Ho Chiahua | Perpendicular MRAM with high magnetic transition and low programming current |
| CZ298424B6 (cs) * | 2005-05-24 | 2007-09-26 | Zentiva, A. S. | Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel |
| EP1842850A1 (en) * | 2006-03-23 | 2007-10-10 | Sandoz AG | Rosiglitazone hydrochloride hemihydrate |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0306228B1 (en) * | 1987-09-04 | 1999-11-17 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| GB9909075D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Plc | Novel pharmaceutical |
-
1999
- 1999-04-20 GB GBGB9909075.5A patent/GB9909075D0/en not_active Ceased
-
2000
- 2000-04-18 PE PE2000000362A patent/PE20010047A1/es not_active Application Discontinuation
- 2000-04-18 MY MYPI20001653A patent/MY125209A/en unknown
- 2000-04-19 RS YUP-816/01A patent/RS50137B/sr unknown
- 2000-04-19 AT AT00920895T patent/ATE262524T1/de not_active IP Right Cessation
- 2000-04-19 EP EP20030079072 patent/EP1411054A1/en not_active Withdrawn
- 2000-04-19 CN CN00801933A patent/CN1327446A/zh active Pending
- 2000-04-19 BR BR0009898-1A patent/BR0009898A/pt not_active Application Discontinuation
- 2000-04-19 SI SI200030340T patent/SI1173437T1/xx unknown
- 2000-04-19 PL PL00351115A patent/PL351115A1/xx unknown
- 2000-04-19 HU HU0200785A patent/HUP0200785A3/hu unknown
- 2000-04-19 SK SK1489-2001A patent/SK284990B6/sk not_active IP Right Cessation
- 2000-04-19 UY UY26113A patent/UY26113A1/es not_active Application Discontinuation
- 2000-04-19 HK HK02105155.8A patent/HK1045304B/zh not_active IP Right Cessation
- 2000-04-19 CO CO00028928A patent/CO5170420A1/es not_active Application Discontinuation
- 2000-04-19 CZ CZ20013758A patent/CZ300934B6/cs not_active IP Right Cessation
- 2000-04-19 KR KR1020017013423A patent/KR100677815B1/ko not_active Expired - Fee Related
- 2000-04-19 EG EG20000501A patent/EG23946A/xx active
- 2000-04-19 WO PCT/GB2000/001527 patent/WO2000063206A2/en not_active Ceased
- 2000-04-19 AP APAP/P/2001/002332A patent/AP1680A/en active
- 2000-04-19 AU AU41311/00A patent/AU773112B2/en not_active Ceased
- 2000-04-19 MX MXPA01010695A patent/MXPA01010695A/es active IP Right Grant
- 2000-04-19 DZ DZ003163A patent/DZ3163A1/xx active
- 2000-04-19 HR HR20010771A patent/HRP20010771B1/xx not_active IP Right Cessation
- 2000-04-19 CN CNA2007101427470A patent/CN101125851A/zh active Pending
- 2000-04-19 EP EP00920895A patent/EP1173437B1/en not_active Expired - Lifetime
- 2000-04-19 DE DE60009276T patent/DE60009276T2/de not_active Expired - Lifetime
- 2000-04-19 UA UA2001117791A patent/UA72245C2/uk unknown
- 2000-04-19 NZ NZ515164A patent/NZ515164A/xx not_active IP Right Cessation
- 2000-04-19 OA OA1200100269A patent/OA11867A/en unknown
- 2000-04-19 PT PT00920895T patent/PT1173437E/pt unknown
- 2000-04-19 ES ES00920895T patent/ES2214267T3/es not_active Expired - Lifetime
- 2000-04-19 AR ARP000101864A patent/AR023563A1/es not_active Application Discontinuation
- 2000-04-19 CA CA002370270A patent/CA2370270A1/en not_active Abandoned
- 2000-04-19 AR ARP000101869A patent/AR023567A1/es unknown
- 2000-04-19 JP JP2000612296A patent/JP4283450B2/ja not_active Expired - Fee Related
- 2000-04-19 DK DK00920895T patent/DK1173437T3/da active
- 2000-04-19 EA EA200101102A patent/EA004769B1/ru not_active IP Right Cessation
- 2000-04-19 IL IL14607700A patent/IL146077A0/xx unknown
- 2000-04-19 TR TR2001/03041T patent/TR200103041T2/xx unknown
- 2000-04-24 TW TW089107634A patent/TWI291463B/zh not_active IP Right Cessation
-
2001
- 2001-10-19 NO NO20015105A patent/NO320573B1/no not_active IP Right Cessation
- 2001-10-19 MA MA26370A patent/MA26784A1/fr unknown
- 2001-10-23 ZA ZA200108721A patent/ZA200108721B/en unknown
- 2001-11-20 BG BG106120A patent/BG65428B1/bg unknown
-
2009
- 2009-02-17 JP JP2009033833A patent/JP2009161544A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW487709B (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, its preparation and its use | |
| EA005115B1 (ru) | Гидрохлорид 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона | |
| JP2009143954A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| TWI291463B (en) | Thiazolidinedione hydrochloride hydrate, pharmaceutical composition comprising the same and process for preparing the same | |
| TW467913B (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt and its preparation | |
| US6664278B2 (en) | Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt | |
| US20080234323A1 (en) | Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride | |
| JP5102849B2 (ja) | N−ヒドロキシ−4−{5−[4−(5−イソプロピル−2−メチル−1,3−チアゾール−4−イル)フェノキシ]ペントキシ}ベンズアミジン2エタンスルホン酸塩、その製造方法およびそれを含む薬学組成物 | |
| TWI345561B (en) | Novel aminoindazole derivatives as medicaments and pharmaceutical compositions including them | |
| JPH03218311A (ja) | 医薬品 | |
| BG107357A (bg) | Тиазолидиндионова сол за лечение hа захарен диабеt | |
| EA005408B1 (ru) | Тартратная соль производного тиазолидиндиона | |
| JP3232503B2 (ja) | 光に安定なベンジルアルコール誘導体含有水溶液 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |